RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

Publisher: La Merie Publishing
Pages: 88
Format: PDF
Product Line:
LMP Full Report
Product Line:
Brief Report
Product Code: LMFR0017
Release Date: February of 2016

950.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but „difficult-to-drug“ target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter. 

The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concers for novel RORgamma modulators were identified. Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.

The report provides an understanding of:

  • The target RORgamma
  • Clinical and non-clinical target validation
  • Clinical lead and up-side indications
  • Drug discovery strategies and technologies
  • Commercial value of drug discovery collaborations
  • R&D timelines from start of screening to first-in-human studies
  • Competitive landscape of RORgamma antagonists
  • Agonists of RORgamma for cancer
  • Profiles of unpartnered technology companies and lead projects
  • R&D Partnerships and their discovery approaches and lead molecules
  • Unpartnered pharmaceutical companies and their programs

 

RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

Table of Contents

1) Introduction

2) Executive Summary

3) Target Background

4) Target validation

• Clinical Success of Anti-IL17 Antibodies

• Non-Clinical Target Validation

• Clinical Lead Indication for RORgamma Antagonists

• Target-related Potential Safety Concerns

5) Drug Discover Approaches & Technologies

• Drug Discovery Collaboration

• Commercial Value of RORgamma Modulator Drug Discovery Collaborations

• R&D Timelines for Discovery of RORgamma Antagonists in Partnership Programs

• Strategies for the Discovery of Nuclear Receptor Ligands

6) Competitive Landscape of RORgamma Modulators

• RORgamma Antagonists for Inflammatory and Autoimmune Diseases

• Agonists of RORgamma for Cancer

7) Corporate Stakeholders

• Unpartnered Technology Companies

• Partnerships

• Unpartnered Pharmaceutical Companies

8) References 


RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

Tables in the report

Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists
Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models
Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models
Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models
Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models
Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models
Table 6: Overview of Partnership Agreements for RORgamma Modulators
Table 7: Special Collaborations for Discovery of RORgamma Antagonists
Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators
Table 9: R&D Timeline for Discovery of RORgamma Antagonists in Partnership Programs
Table 10: Technologies for Discovery of RORgamma Antagonists
Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development
Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies
Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical R&D
Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs
Table 15: RORgamma Agonists Discovery & Development Programs
Table 16: Technology and Pharma Companies with RORgamma Modulator R&D


RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists

Companies mentioned in the report

4SC Discovery
Advinus Therapeutics
Amgen
Argenta
Arrien Pharmaceuticals
AstraZeneca
Aurigene Discovery Technologies
Biogen
Boehringer Ingelheim
Brickell Biotech
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Exelixis
Genfit
GlaxoSmithKline
Glenmark Pharmaceuticals
Innovimmune Biotherapeutics
Janssen Biotech
Japan Tobacco
Karo Bio
Lycera
Merck
Nuevolution
ORCA Pharmaceuticals
Orphagen Pharmaceuticals
Pfizer
Phenex Pharmaceuticals
Piramal (& Krish Biotech)
Roche
Takeda Pharmaceutical Co.
Teijin Pharma
Tempero Pharmaceuticals
Visionary Pharmaceuticals
Vitae Pharmaceuticals



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top